ReviewJournal of thoracic disease2019
Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies.
Review in Journal of thoracic disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Article
- Clinical and translational roles of circulating tumor cells in non-small cell and small cell lung cancer: a narrative review.Journal of thoracic disease · 2026Review
- Epigenetic modulation of CTCs as a novel therapeutic target in oncology.Molecular and cellular biochemistry · 2026Review
- Evaluating circulating tumour cell enrichment techniques to establish an appropriate method for clinical application in glioblastomas.Frontiers in neurology · 2024Article
- Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer.International journal of molecular sciences · 2023Review
- High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells.Nature communications · 2022Article
- Does GD2 synthase (GD2S) detect cancer stem cells in blood samples of breast carcinomas?Journal of applied biomedicine · 2021Article
- Progress and application of circulating tumor cells in non-small cell lung cancer.Molecular therapy oncolytics · 2021Review
- Circulating tumour cells and circulating cell-free DNA in patients with lung cancer: a comparison between thoracotomy and video-assisted thoracoscopic surgery.BMJ open respiratory research · 2021Article
- Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.Cancers · 2021Review
- Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients.Scientific reports · 2021Article
- Review
- Evaluation of Monocarboxylate Transporter 4 (Frontiers in cell and developmental biology · 2021Article
- Tumor Hypoxia and Circulating Tumor Cells.International journal of molecular sciences · 2020Review
- Genomic Instability in Circulating Tumor Cells.Cancers · 2020Review
- Clinical significance of circulating tumor cells and metabolic signatures in lung cancer after surgical removal.Journal of translational medicine · 2020Article
- Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Precision Detection Technology: Equipping Precision Oncology with Wings.Journal of oncology · 2020Review
- Summer School in Flow Cytometry for Immunology: Report From a Successful ESCCA Experience.EJIFCC · 2019Article
- Identification of plasma exosomes long non-coding RNA HAGLR and circulating tumor cells as potential prognosis biomarkers in non-small cell lung cancer.Translational cancer research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growing evidences for tumor heterogeneity confirm that single-tumor biopsies frequently fail to reveal the widespread mutagenic profile of tumor. Repeated biopsies are in most cases unfeasible, especially in advanced cancers. We describe here how circulating tumor cells (CTCs) isolated from minimally invasive blood sample might inform us about intratumor heterogeneity, tumor evolution and treatment resistance. We also discuss the advances of CTCs research, most notably in molecularly selected non-small cell lung cancer (NSCLC) patients, highlighting challenges and opportunities related to personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.